Strategy and progress of stereotactic body radiotherapy for renal cell carcinoma
10.3760/cma.j.cn112271-20230613-00191
- VernacularTitle:肾细胞癌的立体定向体部放射治疗策略及进展
- Author:
Lixiong SHUAI
1
;
Zhifei CAO
;
Yongsheng ZHANG
Author Information
1. 苏州大学附属第二医院病理科，苏州 215004
- Keywords:
Renal cell carcinoma;
Stereotactic body radiotherapy;
Immunotherapy
- From:
Chinese Journal of Radiological Medicine and Protection
2023;43(11):929-933
- CountryChina
- Language:Chinese
-
Abstract:
Renal cell carcinoma (RCC) is one of the most aggressive malignancies in the genitourinary system with a poor prognosis, especially in patients with RCC who have metastases. RCC is conventionally considered not sensitive to radiotherapy. Compared with conventional radiotherapy, stereotactic body radiotherapy (SBRT) has the characteristics of higher precision, higher irradiation dose, and less damage to the surrounding tissue. In recent years, SBRT has shown definite efficacy in the treatment of primary and advanced metastatic RCC. SBRT combined with targeted therapy and immunotherapy can improve the local tumor control rate and cause fewer adverse reactions in patients with primary and advanced metastatic RCC. This article reviews the literature on the strategy and progress of SBRT in combination with targeted therapy and immunotherapy.
